Effects of several antifungal drug combinations against clinical and environmental isolates of Cryptococcus neoformans from China

被引:7
作者
Zhu, LP [1 ]
Gil-Lamaignere, C [1 ]
Müller, FMC [1 ]
机构
[1] Univ Wurzburg, Dept Pediat, Wurzburg, Germany
关键词
Cryptococcus neoformans; antifungal agents; combinations; susceptibility;
D O I
10.1111/j.1439-0507.2004.00998.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The in vitro interactions of caspofungin (CSP) with terbinafine (TRB) and ravuconazole (RVC) with 5-fluorocytosine (5-FC) were tested against 82 clinical and environmental isolates of Cryptococcus neoformans from China. The interaction of CSP with TRB proved synergistic against those isolates with a CSP MIC less than or equal to2 mug ml(-1) (5% of the isolates), additive against 42% of the isolates and indifferent against 53%. The effects of RVC with 5-FC were synergistic, additive or indifferent against 8%, 26% and 67% of the isolates, respectively. No antagonistic effects were found among any of the drugs. The combinations of CSP with TRB and RVC with 5-FC may display beneficial effects in a strain-dependent manner, while in no case showed antagonistic effects. These data might be of use to design safer and more efficient treatments for patients with cryptococcosis and warrant further evaluation.
引用
收藏
页码:319 / 325
页数:7
相关论文
共 50 条
  • [21] Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil
    Andrade-Silva, Leonardo
    Ferreira-Paim, Kennio
    Mora, Delio Jose
    Da Silva, Paulo Roberto
    Andrade, Anderson Assuncao
    Araujo, Natalia Evelyn
    Pedrosa, Andre Luiz
    Silva-Vergara, Mario Leon
    MEDICAL MYCOLOGY, 2013, 51 (06) : 635 - 640
  • [22] Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans
    Teymuri, Mostafa
    Shams-Ghahfarokhi, Masoomeh
    Razzaghi-Abyaneh, Mehdi
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 41
  • [23] Killer activity at different pHs against Cryptococcus neoformans var. neoformans serotype A by environmental yeast isolates
    Criseo, G
    Gallo, M
    Pernice, A
    MYCOSES, 1999, 42 (11-12) : 601 - 608
  • [24] Genotypic diversity in clinical and environmental isolates of Cryptococcus neoformans from India using multilocus microsatellite and multilocus sequence typing
    Prakash, Anupam
    Sundar, Gandhi
    Sharma, Brijesh
    Hagen, Ferry
    Meis, Jacques F.
    Chowdhary, Anuradha
    MYCOSES, 2020, 63 (03) : 284 - 293
  • [25] In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs
    Tay, S. T.
    Haryanty, T. Tanty
    Ng, K. P.
    Rohani, M. Y.
    Hamimah, H.
    MYCOSES, 2006, 49 (04) : 324 - 330
  • [26] Genetic characterization of environmental isolates of the Cryptococcus neoformans species complex from Brazil
    Trilles, L
    Lazéra, M
    Wanke, B
    Theelen, B
    Boekhout, T
    MEDICAL MYCOLOGY, 2003, 41 (05) : 383 - 390
  • [27] A Peptide from Budding Yeast GAPDH Serves as a Promising Antifungal against Cryptococcus neoformans
    Zhang, Yang
    Zhou, Liyan
    Liu, Yan
    Zhao, Xi
    Lian, Xianqiang
    Zhang, Jie
    Zhao, De
    Wang, Yujuan
    Zhong, Jin
    Wang, Junfeng
    Wang, Hongli
    Wang, Linqi
    Fu, Yu, V
    MICROBIOLOGY SPECTRUM, 2022, 10 (01):
  • [28] Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark
    Hagen, Ferry
    Jensen, Rasmus Hare
    Meis, Jacques F.
    Arendrup, Maiken Cavling
    MYCOSES, 2016, 59 (09) : 576 - 584
  • [29] Phenotypic Diversity of Cryptococcus neoformans var. neoformans Clinical Isolates from Localized and Disseminated Infections
    Birkenfeld, Zena M.
    Dittel, Nikita
    Harrer, Thomas
    Stephan, Christoph
    Kiderlen, Albrecht F.
    Rickerts, Volker
    MICROORGANISMS, 2022, 10 (02)
  • [30] The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans
    Trieu Phan Hai
    Anh Duong Van
    Nguyen Thi Thuy Ngan
    Le Thanh Hoang Nhat
    Nguyen Phu Huong Lan
    Chau, Nguyen V. Vinh
    Thwaites, Guy E.
    Krysan, Damian
    Day, Jeremy N.
    MYCOSES, 2019, 62 (09) : 818 - 825